Novavax

Novavax

Yahoo Finance • 6 days ago

WHO begins experimental Ebola trial as Congo outbreak claims 500+ lives

Patients infected with the Bundibugyo strain of Ebola have begun receiving experimental treatments in a World Health Organization-sponsored clinical trial aimed at improving care for the rare viral disease, which has claimed more than 500... Full story

Yahoo Finance • 10 days ago

Novavax (NVAX) Stock Moves 1.36%: What You Should Know

In the latest trading session, Novavax (NVAX) closed at $9.59, marking a +1.36% move from the previous day. Meanwhile, the Dow gained 1.14%, and the Nasdaq, a tech-heavy index, lost 0.8%. Coming into today, shares of the vaccine maker had... Full story

Yahoo Finance • 10 days ago

1 Healthcare Stock with Impressive Fundamentals and 2 We Turn Down

1 Healthcare Stock with Impressive Fundamentals and 2 We Turn Down Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare st... Full story

Yahoo Finance • last month

Novavax set for a seventh straight decline

Shares of Novavax (NVAX [https://seekingalpha.com/symbol/NVAX]) fell 2.84% to $8.38 in the afternoon trade on Tuesday, adding to a six-session slide. The stock has fallen around 18% between June 1 and June 8, compared to a 2.56% decline i... Full story

Yahoo Finance • 2 months ago

3 Reasons NVAX is Risky and 1 Stock to Buy Instead

Novavax has had an impressive run over the past six months as its shares have beaten the S&P 500 by 27.6%. The stock now trades at $9.21, marking a 37.6% gain. This was partly due to its solid quarterly results, and the run-up might have i... Full story

Yahoo Finance • 2 months ago

GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know

What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years. Healthcare companie... Full story

Yahoo Finance • 2 months ago

The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call

Novavax delivered first quarter results that surpassed Wall Street’s revenue and earnings estimates, leading to a significant positive market reaction. Management attributed the quarter’s performance to strong partner-driven revenue stream... Full story

Yahoo Finance • 2 months ago

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

An outbreak of the hantavirus on a cruise ship recently sparked a bit of a rally in the pharmaceutical and biotech industries. While no one hopes this will become a global health crisis, if it does, those companies that develop and market... Full story

Yahoo Finance • 2 months ago

Memory chip stocks hit record highs, pharma reacts to hantavirus concerns

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the day's top trending stock tickers, including memory chip stocks Micron Technology (MU), Intel (INTC), and Qualcomm (QCOM) opening at rec... Full story

Yahoo Finance • 2 months ago

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Quick Read Moderna (MRNA) stock surged on renewed Hantavirus vaccine interest following a cruise ship outbreak, with Q1 revenue beating consensus at $389M versus $236M expected, driven by $311M in international product sales. Pfizer (PFE)... Full story

Yahoo Finance • 3 months ago

Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Regeneron (NASDAQ:REGN) and the best and worst performers in the biotechnology ind... Full story

Yahoo Finance • 3 months ago

Spotting Winners: AbbVie (NYSE:ABBV) And Therapeutics Stocks In Q4

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie (NYSE:ABBV). Over the next few years, therap... Full story

Yahoo Finance • 3 months ago

Report on COVID vaccine benefits being delayed at CDC: WaPo

[CDC Centers for Disease Control and Prevention] The acting director of the Centers for Disease Control and Prevention, Jay Bhattacharya, has delayed the publication of a CDC report indicating that COVID vaccines cut the risk of ER visits... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Shah Capital intends to vote against Novavax's board nominees, executive compensation

By Sneha S K and Sriparna Roy April 8 (Reuters) - Activist investor Shah Capital plans to vote against the re-election of board nominees and ‌the executive compensation package at Novavax's upcoming annual meeting, renewing ‌pressure for... Full story

Yahoo Finance • 3 months ago

2 Growth Stocks Set to Flourishand 1 We Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajec... Full story

Yahoo Finance • 4 months ago

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the... Full story

Yahoo Finance • 4 months ago

Trump administration reportedly shortlisting CDC nominees

[Centers for disease control and prevention sign] sshepard Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Dise... Full story

Yahoo Finance • 4 months ago

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic companies, which develop a wide variety of treatments for... Full story

Yahoo Finance • 4 months ago

FDA vaccine chief to leave the agency again

[FDA Headquarters] For the second time in less than a year, Vinay Prasad, the head of the U.S. Food and Drug Administration’s vaccines unit, is leaving the agency, according to a statement from the FDA commissioner, Marty Makary. Prasad... Full story